



**Bharat Immunologicals & Biologicals Corporation Limited**

**BIBCOL**

CIN – L24232UP1989GOI010542 (A Govt. of India Undertaking)

Regd. Office: Vill. Chola, Bulandshahr(UP)-Pin 203203

Phone (09458096110), Tele Fax -05732 238757

Email – [sklalacs@yahoo.co.in](mailto:sklalacs@yahoo.co.in) Website- [www.bibcol.com](http://www.bibcol.com)

No.BIB/CS/SE/UAFR-Q3/2021-22

Date 08.02.2022

To  
The Listing Department  
Bombay Stock Exchange  
Phiroze jeejeebhoy Tower  
25, Dalal Street, Mumbai – 400001

**Sub: Submission of Unaudited Quarterly Financial Results for the quarter ended  
December 2021 as Compliance of LODR 2015**

Sir/Madam,

In pursuance of the LODR with Stock Exchange, please find enclosed the Unaudited quarterly financial results for the quarter ended December 2021 approved by the Board of the Company in its Meeting on 08.02.2022.


The XBRL filing will be made succeeding to this.

Submitted please.

Thanking you,

For **BHARAT IMMUNOLOGICAL AND BIOLOGICAL  
CORPORATION LIMITED (BIBCOL)**



  
Sandip Kumar Lal  
(G. M./Company Secretary)

**BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED**  
Registered office at VILLAGGE CHOLA PS-KOTOALI DEHAT BULANSAHAR UTTAR PRADESH UP  
203203

CIN:- L24232UP1989GOI010542

Part I

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 31-12-2021**  
**Selected Information for the Period Ended 31-12-2021**

(INR in Lakh)

S.No	Particulars	3 Months Ended on 31-12-2021	Preceding 3 Months Ended on 30-09-2021	Corresponding 3 Months Ended in the previous year 31-12-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	<b>INCOME</b>				
	a) Income from Operations	1,743.05	2,470.16	2,519.89	8,533.36
	b) Other Income	12.38	21.73	120.03	983.19
	<b>Total Revenue (1)</b>	<b>1,755.43</b>	<b>2,491.89</b>	<b>2,639.92</b>	<b>9,516.55</b>
2	<b>EXPENDITURE</b>				
	a) Cost of Material Consumed	1,944.58	1,420.29	1,200.22	6,105.99
	b) Purchase of Stock in Trade	-	-	-	-
	c) Change in Inventory of Finished Goods, Work in Progress and Stock in Trade	-1,049.60	775.60	1,093.79	2,014.53
	d) Employees Benefits	319.06	305.44	264.20	1,575.25
	e) Finance Cost	153.85	122.78	129.61	477.02
	f) Depreciations and Amortization Expense	4.07	5.75	5.92	23.67
	g) Other Expense	427.45	318.03	189.10	1,043.51
	<b>Total Expense (2)</b>	<b>1,799.41</b>	<b>2,947.89</b>	<b>2,882.84</b>	<b>11,239.97</b>
3	Profit/ (Loss) before exceptional items (1-2)	-43.98	-456.00	-242.92	-1,723.42
4	Tax Expense				
	a) Current Tax	-	-	-	-
	b) Deferred Tax	-11.04	480.09	-53.45	-415.50
5	<b>Profit/ (Loss) from continuing Operations (3-4)</b>	<b>-32.94</b>	<b>-936.09</b>	<b>-189.47</b>	<b>-1,307.92</b>
6	Other Comprehensive Income/(Loss) (Net of Taxes)	-	-	-	-
7	Total Comprehensive Income/ (Loss) for the period (5+6)	-32.94	-936.09	-189.47	-1,307.92
8	Paid Up Equity Share Capital (Face Value of INR 10/- each)	4,318.00	4,318.00	4,318.00	4,318.00
9	Earnings Per Share (of INR 10/- each) not annualized				
	a) Basic	-0.08	-2.17	-0.44	-3.03
	b) Diluted	-0.08	-2.17	-0.44	-3.03

Note:- Refer our Note Separately





**Part II**  
**Selected Information for the Period Ended 31-12-2021**

S. No	Particulars	3 Months Ended on 31-12-2021	Preceding 3 Months Ended on 30-09-2021	Corresponding 3 Months Ended in the previous year 31-12-2020	Previous Year Ended as on 31-03-2021
		(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
A1	<b>PARTICULARS OF SHAREHOLDING</b>				
	Public shareholding				
	- Number of Shares	17,594,000.00	17,594,000.00	17,594,000.00	17,594,000.00
	- Percentage of shareholding	40.75	40.75	40.75	40.75
A2	Promoters and Promoters Group shareholding				
	a) Pledged/ Encumbered				
	- Number of Shares	-	-	-	-
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	-	-	-	-
	- Percentage of shareholding (as a% of the total share capital of the company)	-	-	-	-
	b) Non - encumbered				
	- Number of Shares	25,586,000.00	25,586,000.00	25,586,000.00	25,586,000.00
	- Percentage of shareholding (as a% of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
	- Percentage of shareholding (as a% of the total share capital of the company)	59.25	59.25	59.25	59.25
<b>B</b>	<b>Particulars</b>	<b>3 Months ended (31-12-2021)</b>			
	<b>INVESTOR COMPLAINTS</b>				
	Pending at the beginning of the quarter	-			
	Received during the quarter	-			
	Disposed of during the quarter	-			
	Remaining unresolved at the end of the quarter	-			

  
*Srip.* 

**Selected Information for the Period Ended 31-12-2021**


(INR in Lakhs)

S. No	Particulars	3 Months Ended on 31-12-2021	Preceding 3 Months Ended on 30-09-2021	Corresponding 3 Months Ended in the previous year 31-12-2020	Previous Year Ended as on 31-03-2021
1	<b>SEGMENT REVENUE</b>				
	Oral Polio Vaccine	1,742.95	2,469.04	2,518.16	8,525.15
	Zinc Dispersible Tablets	-	-	-	0.16
	BIB Sweet Tablets	-	-	-	0.01
	BIBSANIT	0.10	1.12	1.73	8.04
	Less: Intersegment revenue	-	-	-	-
	<b>Net Sales/ Income from operations</b>	<b>1,743.05</b>	<b>2,470.16</b>	<b>2,519.89</b>	<b>8,533.36</b>
2	<b>SEGMENT RESULTS (Profit Before Tax)</b>				
	Oral Polio Vaccine	-43.93	-455.51	-240.73	-1,714.63
	Zinc Dispersible Tablets	-0.04	-0.03	-1.50	-5.11
	BIB Sweet Tablets	-	-	-	-
	BIBSANIT	-0.01	-0.46	-0.69	-3.68
	Less: Unallocable expenditure net off unallocable Income	-	-	-	-
	<b>Total Profit before Tax</b>	<b>-43.98</b>	<b>-456.00</b>	<b>-242.92</b>	<b>-1,723.42</b>
3	<b>CAPITAL EMPLOYED (Segment Assets less Liabilities)</b>				
	Oral Polio Vaccine	19,140.69	12,604.12	3,774.85	5,138.06
	Zinc Dispersible Tablets	-226.05	7.34	-230.13	-710.39
	BIB Sweet Tablets	-	-	0.03	0.03
	BIBSANIT	-	78.00	-	-
	Others	-861.18	39.48	-0.38	-257.61
	<b>Total Capital employed</b>	<b>18,053.46</b>	<b>12,728.94</b>	<b>3,544.37</b>	<b>4,170.09</b>




## Notes to the Results

1. The above Un-Audited results for the Quarter ended 31<sup>st</sup> December, 2021 have been review by the Audit Committee and were taken on record by the Board of Directors in their meeting held on February 08, 2022.
2. Valuation of Closing Stock has been done on the basis of Net realizable value.
3. In quarters, depreciation has been charged on the basis of Companies Act 2013.
4. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rule 2015 (Ind AS), prescribed under Section 133 of the Companies Act, 2013, and other recognized accounting practices and policies to the extent applicable.
5. The format for unaudited quarterly results as prescribed in SEBI's Circular dated November 30, 2015 has been modified to comply with requirements of SEBI's Circular dated July 5, 2016, Ind AS and Schedule III (Division II) to the Companies Act, 2013 applicable to companies that are required to comply with Ind AS.
6. The statement does include Ind AS compliant results for the preceding quarter and previous year ended 31.03 2021.
7. Segment information as per Ind AS 108 has been given above as Segment Reporting. The Company is currently engaged in production of Oral Polio Vaccine, Zinc Dispersible Tablets, Sanitizer and Sweetener.
8. The Ind As complaint corresponding figures in the previous year have been subjected to review / audited. However, the company's management has exercised necessary due diligence to ensure that such financial results provide a true and fair view of its affairs.
9. The reconciliation of net profit or loss reported in accordance with Indian GAAP to total comprehensive income in accordance with Ind AS. For Table, kindly refer Corporate Announcements on [www.bseindia.com](http://www.bseindia.com).
10. Previous year/quarter figures have been regrouped/re-arranged wherever necessary, to make it comparable.



**(Sanjay Kumar Mishra)**  
**Managing Director**

**Date :- 08.02.2022**



Bharat Immunologicals & Biologicals Corporation Limited		
Village Chola, P S - Kotoali Dehat Bulandshahr, Uttar Pradesh, India - 203203		
CIN :- L24232UP1989GOI010542		
Cash Flow Statement for the period ended 31.12.2021		
(Rupees in Lacs)		
PARTICULARS	as on 31st December 2021	as on 31st March 2021
<b>A</b>	<b>CASH FLOW FROM OPERATING ACTIVITIES :</b>	
	(491.30)	(2,420.78)
	-	-
	15.71	23.67
	-	3,168.07
	391.52	477.74
	-	-
	(49.21)	(66.87)
	<b>(133.28)</b>	<b>1,181.83</b>
	<b>ADJUSTMENT FOR:</b>	
	(1,814.06)	1,760.33
	(4,298.48)	3,822.84
	(583.21)	187.22
	2,421.76	(2,873.83)
	80.15	374.57
	(238.95)	111.65
	-	-
	(346.45)	(3,578.96)
	43.94	11.57
	299.74	180.46
	<b>(4,568.84)</b>	<b>1,177.69</b>
<b>B</b>	<b>CASH FLOW FROM INVESTING ACTIVITIES</b>	
	-	-
	-	-
	49.21	66.87
	<b>49.21</b>	<b>66.88</b>
<b>C</b>	<b>CASH FLOW FROM FINANCING ACTIVITIES</b>	
	-	-
	-	(3,168.07)
	4,929.63	2,425.49
	(391.52)	(477.74)
	<b>4,538.12</b>	<b>(1,220.30)</b>
	18.50	24.19
	<b>ADD:</b>	
	122.69	98.50
	<b>141.04</b>	<b>122.69</b>
See accompanying notes forming part of the financial statements in terms of our report attached.		



**BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION LIMITED**  
Registered office at VILLAAGE CHOLAPS-KOTOALI DEHAT BULANSAHAR UTTAR  
PRADESH UP 203203

CIN:- L24232UP1989GOI010542

**Statement of Assets and Liabilities as at 31st March, 2021**

Particulars		As at 31st December, 2021	As at 31st March, 2021
<b>A</b>	<b>ASSETS</b>		
<b>1</b>	<b>Non-current assets</b>		
	(a) Property, Plant and Equipment	8,413.64	422.84
	(b) Capital work-in-progress	3,190.00	3,190.00
	(c) Financial Assets	1,490.62	1,251.67
	(d) Other non-current assets	44.84	44.84
	(e) Non Current Tax Assets (Net)	76.37	84.54
	(f) Deferred tax assets (net)	1,725.55	2,009.25
		<b>14,941.03</b>	<b>7,003.15</b>
<b>2</b>	<b>Current assets</b>		
	(a) Inventories	5,647.53	1,349.04
	(b) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	1,815.11	1.05
	(ii) Cash and cash equivalents	141.04	122.70
	(iii) Bank balances other than (ii) above	631.14	930.88
	(c) Other current assets	1,583.12	991.75
		<b>9,817.94</b>	<b>3,395.42</b>
	<b>Total</b>	<b>24,758.97</b>	<b>10,398.58</b>
<b>B</b>	<b>EQUITY AND LIABILITIES</b>		
<b>1</b>	<b>Equity</b>		
	(a) Equity Share capital	4,318.00	4,318.00
	(b) Other Equity	6,317.00	(913.89)
		<b>10,635.00</b>	<b>3,404.11</b>
<b>2</b>	<b>Non-current liabilities</b>		
	(a) Deferred Grant	-	-
	(b) Long Term Provisions	627.58	585.39
		<b>627.58</b>	<b>585.39</b>
<b>3</b>	<b>Current liabilities</b>		
	(a) Financial Liabilities		
	(i) Borrowings	7,658.97	2,729.34
	(ii) Trade payables	3,901.08	1,479.32
	(iii) Other Financial Liabilities	93.75	49.81
	(b) Deferred Grant	-	-
	© Short Term Provisions	479.90	441.95
	(d) Other Current liabilities	1,362.21	1,708.66
		<b>13,495.91</b>	<b>6,409.07</b>
	<b>Total</b>	<b>24,758.97</b>	<b>10,398.58</b>

